RT Journal Article
SR Electronic
T1 CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.07.24.220715
DO 10.1101/2020.07.24.220715
A1 Brien K. Haun
A1 Chih-Yun Lai
A1 Caitlin A. Williams
A1 Teri Ann Wong
A1 Michael M. Lieberman
A1 Laurent Pessaint
A1 Hanne Andersen-Elyard
A1 Axel T. Lehrer
YR 2020
UL http://biorxiv.org/content/early/2020/07/26/2020.07.24.220715.abstract
AB The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immunogen delivery, adjuvants may greatly impact protective efficacy of a SARS-CoV-2 vaccine. To investigate adjuvant suitability, we formulated protein subunit vaccines consisting of the recombinant S1 domain of SARS-CoV-2 Spike protein alone or in combination with either CoVaccine HT™ or Alhydrogel. CoVaccine HT™ induced high titres of antigen-binding IgG after a single dose, facilitated affinity maturation and class switching to a greater extent than Alhydrogel and elicited potent cell-mediated immunity as well as virus neutralising antibody titres. Data presented here suggests that adjuvantation with CoVaccine HT™ can rapidly induce a comprehensive and protective immune response to SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.